A woman shows off her 23andMe spit vial before mailing it to the company’s labs. Image by YouTube

By Ari Feldman March 7, 2018

23andMe recently received FDA approval to inform customers of its popular mail-in DNA tests about their risk for breast cancer, the Atlantic reported. 23andMe is the first company to get federal approval for a direct-to-consumer genetic cancer risk test.

The FDA sanctioned 23andMe’s request to tell customers whether they have mutations on the genes BRCA-1 or BRCA-2 genes — mutations that are strongly linked to the development of breast cancer.

Another Silicon Valley company, Color Genomics, launched a similar breast cancer genetics test in 2015. But the company — owned by an Israeli — was only allowed to sell its mail-in test through physicians.

Forwarding the News

Thoughtful, balanced reporting from the Forward and around the web, bringing you updated news and analysis each day.

Terms(Required)

I agree to the Forward's Terms of Service and Privacy Policy

Email(Required)

23andMe used to offer BRCA tests when it first was founded, but was forced to suspend all its genetic health testing by the FDA in 2013.

“Worrying about the many current 23andMe customers who have one of or more of these variants has caused me sleepless nights,” 23andMe CEO Anne Wojcicki wrote in a blog post Tuesday.

BRCA gene mutations mainly affect women, and certain variants of the mutation can increase risk of breast and ovarian cancer by nearly 50%.

Contact Ari Feldman at [email protected] or on Twitter @aefeldman

The Forward is free to read, but it isn’t free to produce

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

This is a great time to support independent Jewish journalism you rely on. Make a gift today!

—  Rachel Fishman Feddersen, Publisher and CEO

Support our mission to tell the Jewish story fully and fairly.

$90 $180

$360

Other amount